X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
ATX101 is a novel investigational configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: ATX101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Details:
Under the agreement, Maruishi will have the exclusive rights to develop and commercialize Allay’s lead investigational drug candidate, ATX101, a non-opioid, bupivacaine-based drug product, and other ultra-sustained analgesic implantable drug candidates for acute pain in Japan.
Lead Product(s): Bupivacaine
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ATX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Maruishi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 18, 2023
Details:
ATX-101 is a small product placed directly into the TKA surgical site in a simple, ‘place & go’ manner designed to add minimal extra complexity and time to the procedure.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: ATX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Evonik
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2022
Details:
Allay intends to proceed into a Phase 2b study of ATX-101 in total knee arthroplasties (TKA, also called total knee replacements) in the United States.
Lead Product(s): Bupivacaine
Therapeutic Area: Orthopedics/Orthopedic Surgery Product Name: ATX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Arboretum Ventures
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 15, 2021
Details:
ATX-101 is a novel configuration of an approved, well-characterized, validated intracellular sodium ion channel blocker, bupivacaine, and a biopolymer that has been designed to provide weeks of pain relief following total knee arthroplasty.
Lead Product(s): Bupivacaine
Therapeutic Area: Neurology Product Name: ATX-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
